Pharmacokinetic implications

M Mayersohn. Ascorbic acid absorption in man-pharmacokinetic implications. Eur J Pharmacol 19 140-142, 1972. 

The pharmacokinetic implications of these findings are not straightforward. One important factor that must also be considered is hepatic extraction, which is higher for lovastatin than for its hydroxy acid metabolite [188], Some lactones are useful prodrugs of HMG-CoA reductase inhibitors due to this organ selectivity coupled with the efficiency of enzymatic hydrolysis. However, other factors may also influence the therapeutic response, in particular the extent and rate of metabolic reactions that compete with or follow hydrolysis, e.g., cytochrome P450 catalyzed oxidations, /3-oxidation, and tau-... 

Cheymol G. Effects of obesity on pharmacokinetics implications for drag therapy. Clin Pharmacokinet. 2000 39 215-231. 

Caccia S. Metabolism of the newer antidepressants-an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998 34 281-302. 

Gidal BE, Sheth R, Parnell J, et al. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003 57 85-93. 

S. Toon and W, F, Trager, "Pharmacokinetic implications of stereoselective changes in plasma-protein binding Warfarin-sulfinpyrazone," /. Pharm. ScL, 73 1671-1673 (1984). 

Gilman, J.T. Therapeutic drug monitoring in neonate and paediatric age group. Problems and clinical pharmacokinetic implications. Clin. Pharmacokinet. 1990, 19, 1-10. 

McNamara DR, Nafziger AN, Menhinick AM, Bertino JS. Jr. A dose-ranging study of gentamicin pharmacokinetics implications for extended interval aminoglycoside therapy. J Clin Pharmacol 2001 41(4) 374-7. 

Woodcock A, Acerbi D, Poll G. Modulite technology pharmacodynamic and pharmacokinetic implications. Respir Med 2002 96(Suppl D) S9-15. 

Klotz, U. (1976) Pathophysiological and disease-induced changes in drug distribution volume pharmacokinetic implications. Clinical Pharmacokinetics, 1, 204-218. 

Sparreboom, A., van Zuylen, L., Brouwer, E., Loos, W.J., de Bruijn, P., Gelderblom, H., Pillay, M., Nooter, K., Stoter, G., and Verweij, J. Cremephor EL-mediated alteration of paclitaxel distribution of human blood Clinical pharmacokinetic implications. Cancer Research 1999 59 1454— 1457. 

Riviere, J.E. and Williams, RL., 1992, Pharmacokinetic implications of changing blood flow in skin, J. Pharm. Set, 81 601-602. 

BrynneN, Svanstrfim C, Aberg-Wistedt A, HallenB, BertlissonL. Fluoxetine inhibits the me-tabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance. BrJ Clin Pharmacol (1999) 48, 553-63. 

Pharmacokinetic Implications of Recent Studies of an Assay Procedure and Urinary Excretion in Man... 

---